Key result
Once-daily fondaparinux matches enoxaparin for 3-month recurrent VTE in acute DVT.
RCT (n=2,205)
Double-blind
Randomized
Yes
Answers are grounded in this paper and cite their sources.
BACKGROUND: The current standard initial therapies for deep venous thrombosis are low-molecular-weight heparin and unfractionated heparin. In a dose-ranging study of patients with symptomatic deep venous thrombosis, fondaparinux had efficacy and a safety profile similar to those of low-molecular-weight heparin (dalteparin). OBJECTIVE: To evaluate whether fondaparinux has efficacy and safety similar to those of enoxaparin in patients with deep venous thrombosis. DESIGN: Randomized, double-blind study. SETTING: 154 centers worldwide. PATIENTS: 2205 patients with acute symptomatic deep venous thrombosis. INTERVENTION: Fondaparinux, 7.5 mg (5.0 mg in patients weighing <50 kg and 10.0 mg in patients weighing >100 kg) subcutaneously once daily, or enoxaparin, 1 mg/kg of body weight, subcutaneously twice daily for at least 5 days and until vitamin K antagonists induced an international normalized ratio greater than 2.0. MEASUREMENTS: The primary efficacy outcome was the 3-month incidence of symptomatic recurrent venous thromboembolic complications. The main safety outcomes were major bleeding during initial treatment and death. An independent, blinded committee adjudicated all outcomes. RESULTS: 43 (3.9%) of 1098 patients randomly assigned to fondaparinux had recurrent thromboembolic events compared with 45 (4.1%) of 1107 patients randomly assigned to enoxaparin (absolute difference, -0.15 percentage point [95% CI, -1.8 to 1.5 percentage points]). Major bleeding occurred in 1.1% of patients receiving fondaparinux and 1.2% of patients receiving enoxaparin. Mortality rates were 3.8% and 3.0%, respectively. LIMITATIONS: Follow-up was incomplete in 0.4% of fondaparinux-treated patients and 1.0% of enoxaparin-treated patients. CONCLUSIONS: Once-daily subcutaneous fondaparinux was at least as effective (not inferior) and safe as twice-daily, body weight-adjusted enoxaparin in the initial treatment of patients with symptomatic deep venous thrombosis.
No takes yet. Share an insight, caveat, or question.
Harry R. Büller (2004) conducted an RCT in Acute symptomatic deep venous thrombosis (n=2,205). Fondaparinux vs. Enoxaparin, 1 mg/kg of body weight, subcutaneously twice daily was evaluated on 3-month incidence of symptomatic recurrent venous thromboembolic complications (Absolute difference -0.15 percentage point, 95% CI -1.8 to 1.5). Once-daily fondaparinux was noninferior to twice-daily enoxaparin for 3-month recurrent venous thromboembolism in acute symptomatic DVT.
Synapse has enriched 10 related papers. Consider them for comparative context: